The stock of Polypid Ltd (PYPD) has seen a 7.92% increase in the past week, with a 30.96% gain in the past month, and a 30.96% flourish in the past quarter. The volatility ratio for the week is 7.95%, and the volatility levels for the past 30 days are at 5.32% for PYPD. The simple moving average for the last 20 days is 15.73% for PYPD stock, with a simple moving average of 18.82% for the last 200 days.
Is It Worth Investing in Polypid Ltd (NASDAQ: PYPD) Right Now?
Additionally, the 36-month beta value for PYPD is 1.25. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for PYPD is 6.66M and currently, short sellers hold a 0.52% ratio of that float. The average trading volume of PYPD on June 24, 2025 was 443.30K shares.
PYPD) stock’s latest price update
The stock price of Polypid Ltd (NASDAQ: PYPD) has surged by 563001 when compared to previous closing price of 3.28, but the company has seen a 7.92% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-16 that PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD ) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that following its recently announced successful SHIELD II phase 3 topline results, it has secured additional funding through the exercise of warrants with aggregate gross proceeds of $26.7 million. The Company anticipates that with this additional funding, PolyPid’s runway would be extended beyond anticipated FDA approval of D-PLEX₁₀₀.
Analysts’ Opinion of PYPD
Many brokerage firms have already submitted their reports for PYPD stocks, with Roth Capital repeating the rating for PYPD by listing it as a “Buy.” The predicted price for PYPD in the upcoming period, according to Roth Capital is $9 based on the research report published on June 05, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see PYPD reach a price target of $11. The rating they have provided for PYPD stocks is “Buy” according to the report published on June 02nd, 2025.
Rodman & Renshaw gave a rating of “Buy” to PYPD, setting the target price at $13 in the report published on January 28th of the current year.
PYPD Trading at 26.46% from the 50-Day Moving Average
After a stumble in the market that brought PYPD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -18.04% of loss for the given period.
Stock Fundamentals for PYPD
The total capital return value is set at -2.24. Equity return is now at value -853.05, with -146.02 for asset returns.
The debt to equity ratio resting at 1.25. The interest coverage ratio of the stock is -29.47.
Currently, EBITDA for the company is -25.83 million with net debt to EBITDA at 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.71.
Conclusion
In conclusion, Polypid Ltd (PYPD) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
